All right. Good morning, again, for I see some familiar face in the last one, but thanks for sticking around. It's good to see everybody, and welcome back to TD Cowen's 46th Annual Healthcare ...

Recursive, agent-driven intelligence promises extraordinary gains, but it also introduces risks that scale faster than human oversight, governance, and intuition. The challenge ahead is not whether ...

Abstract: In industrial measurements, when signal reception is affected by hardware defects or asymmetric interference, I/Q imbalance can occur, which may result in the noise exhibiting noncircular ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...

Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...